# EPO-4-Rhesus Study

> **NCT03104426** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research** · enrollment: 42 (estimated)

## Conditions studied

- Erythroblastosis, Fetal
- Erythroblastosis Fetalis, Rh Disease
- Erythroblastosis Fetalis Due to RH Antibodies
- Erythroblastosis Fetalis Due to Isoimmunization

## Interventions

- **DRUG:** Darbepoetin Alfa

## Key facts

- **NCT ID:** NCT03104426
- **Lead sponsor:** Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-31
- **Primary completion:** 2020-08
- **Final completion:** 2020-08
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2019-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03104426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03104426, "EPO-4-Rhesus Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03104426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*